Cover Image
市場調查報告書

Hemostemix Ltd:產品平台分析

Hemostemix Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 341512
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Hemostemix Ltd:產品平台分析 Hemostemix Ltd - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 23 Pages
簡介

Hemostemix, Ltd.是致力於開發及商品化未改善病情的創新的血源性細胞療法,臨床階段的生物科技企業。該公司的產品使用血源性細胞療法治療危急性肢體缺血和心絞痛、缺血性心臟疾病、伯格氏病等。

本報告提供Hemostemix Ltd 的治療藥開發平台的現狀及各開發階段比較分析、藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估及中止的計劃相關資訊等

Hemostemix Ltd的基本資料

  • Hemostemix Ltd概要
  • 主要資訊
  • 企業資料

Hemostemix Ltd:R&D概要

  • 主要的治療範圍

Hemostemix Ltd:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Hemostemix Ltd:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Hemostemix Ltd:藥物簡介

  • ACP-01
  • NCP-01
  • BCP-01

Hemostemix Ltd:開發平台分析

  • 各給藥途徑
  • 各分子類型

Hemostemix Ltd:最近的開發平台趨勢

Hemostemix Ltd:暫停中的計劃

Hemostemix Ltd:總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC07542CDB

Summary

Global Markets Direct's, 'Hemostemix Ltd - Product Pipeline Review - 2015', provides an overview of the Hemostemix Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hemostemix Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hemostemix Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hemostemix Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hemostemix Ltd's pipeline products

Reasons to buy

  • Evaluate Hemostemix Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hemostemix Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hemostemix Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hemostemix Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hemostemix Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hemostemix Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hemostemix Ltd Snapshot
    • Hemostemix Ltd Overview
    • Key Information
    • Key Facts
  • Hemostemix Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Hemostemix Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Hemostemix Ltd - Pipeline Products Glance
    • Hemostemix Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Hemostemix Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hemostemix Ltd - Drug Profiles
    • ACP-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCP-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCP-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hemostemix Ltd - Pipeline Analysis
    • Hemostemix Ltd - Pipeline Products by Route of Administration
    • Hemostemix Ltd - Pipeline Products by Molecule Type
  • Hemostemix Ltd - Recent Pipeline Updates
  • Hemostemix Ltd - Dormant Projects
  • Hemostemix Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hemostemix Ltd, Key Information
  • Hemostemix Ltd, Key Facts
  • Hemostemix Ltd - Pipeline by Indication, 2015
  • Hemostemix Ltd - Pipeline by Stage of Development, 2015
  • Hemostemix Ltd - Monotherapy Products in Pipeline, 2015
  • Hemostemix Ltd - Phase II, 2015
  • Hemostemix Ltd - Phase I, 2015
  • Hemostemix Ltd - Preclinical, 2015
  • Hemostemix Ltd - Discovery, 2015
  • Hemostemix Ltd - Pipeline by Route of Administration, 2015
  • Hemostemix Ltd - Pipeline by Molecule Type, 2015
  • Hemostemix Ltd - Recent Pipeline Updates, 2015
  • Hemostemix Ltd - Dormant Developmental Projects,2015
  • Hemostemix Ltd, Other Locations

List of Figures

  • Hemostemix Ltd - Pipeline by Top 10 Indication, 2015
  • Hemostemix Ltd - Pipeline by Stage of Development, 2015
  • Hemostemix Ltd - Monotherapy Products in Pipeline, 2015
  • Hemostemix Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Hemostemix Ltd - Pipeline by Top 10 Molecule Type, 2015
Back to Top